Hutchison Medi Pharma

Company snapshot

Hutchmed Europe is a pharma organization headquartered in EU. Primary therapeutic focus areas include Lymphoma, Primary immune thrombocytopenia (ITP). NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (4).

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Hutchison Medi Pharma. Not investment advice.

• What is Hutchison Medi Pharma?

  Hutchmed Europe is a pharma organization headquartered in EU. Primary therapeutic focus areas include Lymphoma, Primary immune thrombocytopenia (ITP). NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, Clinic

• Is Hutchison Medi Pharma publicly traded?

  Hutchison Medi Pharma appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Hutchison Medi Pharma develop or market?

  We link 6 drug profile(s) where Hutchison Medi Pharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/hutchmed-europe-b-v#company-drugs.

• What are the latest developments for Hutchison Medi Pharma?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Hutchison Medi Pharma focus on?

  Hutchison Medi Pharma focuses on Lymphoma, Primary immune thrombocytopenia (ITP) based on our analysis of their pipeline programs and drug development activities.